{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:25:04Z","timestamp":1769631904628,"version":"3.49.0"},"reference-count":21,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11,1]]},"abstract":"<jats:p>OBJECTIVE. This study was conducted to confirm the absence of immune interference of 2 doses of RIX4414 (Rotarix) on routine infant vaccinations in the United States.<\/jats:p><jats:p>STUDY DESIGN. A total of 484 healthy infants aged 6 to 12 weeks were randomly assigned to 1 of 2 groups to receive 3 doses of Pediarix (combined diphtheria-tetanus-acellular pertussis-hepatitis B-poliovirus vaccine [DTaP-HBV-IPV]), Prevnar (7-valent pneumococcal conjugate vaccine [PCV7]), and ActHIB (Haemophilus influenzae type b conjugate vaccine [Hib]) at 2, 4, and 6 months of age with RIX4414 either coadministered at 2 and 4 months (Co-ad) or administered separately at 3 and 5 months (Sep-ad). Serum antibodies were measured 1 month after dose 3 of the DTaP-HBV-IPV, PCV7, and Hib vaccines.<\/jats:p><jats:p>RESULTS. Antibody responses to all antigens were similar in infants in both the Co-ad and Sep-ad groups. Seroprotective antibody concentrations against diphtheria, tetanus, hepatitis B, and poliovirus types 1, 2, and 3 were achieved by \u226597.9% of the infants in both groups. Antipolyribosyl ribitol phosphate antibody levels of \u22651.0 \u03bcg\/mL were achieved by 88.3% to 89.4% of infants in both groups. In both groups, \u226597.8% of the infants were seropositive for antipertussis antibodies and the 7 pneumococcal serotypes. Predefined criteria for noninferiority between groups were reached for all antigens.<\/jats:p><jats:p>CONCLUSIONS. Two doses of RIX4414 coadministered with routine infant vaccines as recommended in the United States (DTaP-HBV-IPV, PCV7, and Hib) did not impair the immune response to any of the coadministered antigens.<\/jats:p>","DOI":"10.1542\/peds.2008-1059","type":"journal-article","created":{"date-parts":[[2008,10,31]],"date-time":"2008-10-31T13:45:14Z","timestamp":1225460714000},"page":"e1062-e1066","source":"Crossref","is-referenced-by-count":44,"title":["Coadministration of RIX4414 Oral Human Rotavirus Vaccine Does Not Impact the Immune Response to Antigens Contained in Routine Infant Vaccines in the United States"],"prefix":"10.1542","volume":"122","author":[{"given":"Penelope H.","family":"Dennehy","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Rhode Island Hospital, Providence, Rhode Island"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen R.","family":"Bertrand","sequence":"additional","affiliation":[{"name":"Lowcountry Medical Associates, Charleston, South Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Silas","sequence":"additional","affiliation":[{"name":"Wee Care Pediatrics, Layton, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Damaso","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, King of Prussia, Pennsylvania and Rixensart, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard R.","family":"Friedland","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, King of Prussia, Pennsylvania and Rixensart, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remon","family":"Abu-Elyazeed","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, King of Prussia, Pennsylvania and Rixensart, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2008,11,1]]},"reference":[{"key":"2021120902382155300_R1","doi-asserted-by":"crossref","unstructured":"Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis.\u20082003;9(5):565\u2013572","DOI":"10.3201\/eid0905.020562"},{"key":"2021120902382155300_R2","doi-asserted-by":"crossref","unstructured":"Glass RI, Parashar UD, Bresee JS, et al. Rotavirus vaccines: current prospects and future challenges. Lancet.\u20082006;368(9532):323\u2013332","DOI":"10.1016\/S0140-6736(06)68815-6"},{"key":"2021120902382155300_R3","doi-asserted-by":"crossref","unstructured":"Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89\u201312. Vaccine.\u20081998;16(4):381\u2013387","DOI":"10.1016\/S0264-410X(97)00210-7"},{"key":"2021120902382155300_R4","doi-asserted-by":"crossref","unstructured":"Salinas B, Perez S, I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J.\u20082005;24(9):807\u2013816","DOI":"10.1097\/01.inf.0000178294.13954.a1"},{"key":"2021120902382155300_R5","doi-asserted-by":"crossref","unstructured":"Phua KB, Emmanuel SC, Goh P, et al. A rotavirus vaccine for infants: the Asian experience. Ann Acad Med Singapore.\u20082006;35(1):38\u201344","DOI":"10.47102\/annals-acadmedsg.V35N1p38"},{"key":"2021120902382155300_R6","unstructured":"Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med.\u20082006;354(1):11\u201322"},{"key":"2021120902382155300_R7","doi-asserted-by":"crossref","unstructured":"Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J.\u20082004;23(10):937\u2013943","DOI":"10.1097\/01.inf.0000141722.10130.50"},{"key":"2021120902382155300_R8","doi-asserted-by":"crossref","unstructured":"Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet.\u20082007;370(9601):1757\u20131763","DOI":"10.1016\/S0140-6736(07)61744-9"},{"key":"2021120902382155300_R9","unstructured":"Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. General recommendations on immunization recommendations of the Advisory Committee on Immunization Practices (ACIP) [published corrections appear in MMWR Morb Mortal Wkly Rep. 2006;55(48):1303; MMWR Morb Mortal Wkly Rep. 2007;56(11):256; and Pediatrics. 2007;119(5):1008]. MMWR Recomm Rep.\u20082006;55(RR-15):1\u201348"},{"key":"2021120902382155300_R10","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics. General recommendations on immunization: recommendations from the advisory committee on immunization practices. Pediatrics.\u20082007;119(5):1008","DOI":"10.1542\/peds.2007-0432"},{"key":"2021120902382155300_R11","unstructured":"American Academy of Family Physicians. Recommended childhood immunization schedule 2008. Available at: www.aafp.org\/online\/en\/home\/clinical\/immunizationres\/child.html. Accessed September 10, 2008"},{"key":"2021120902382155300_R12","doi-asserted-by":"crossref","unstructured":"Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis.\u20081989;159(1):79\u201388","DOI":"10.1093\/infdis\/159.1.79"},{"key":"2021120902382155300_R13","doi-asserted-by":"crossref","unstructured":"Clopper CJ, Pearson ES. The use of confidence of fiducial limits illustrated in the case of the binomial. Biometrika.\u20081934;26:404\u2013413","DOI":"10.1093\/biomet\/26.4.404"},{"key":"2021120902382155300_R14","doi-asserted-by":"crossref","unstructured":"Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med.\u20081998;17(8):873\u2013890","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I"},{"key":"2021120902382155300_R15","doi-asserted-by":"crossref","unstructured":"Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J.\u20082005;24(6):481\u2013488","DOI":"10.1097\/01.inf.0000164763.55558.71"},{"key":"2021120902382155300_R16","doi-asserted-by":"crossref","unstructured":"Araujo EC, Clemens SA, Oliveira CS, et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants [in Portugese]. J Pediatr (Rio J).\u20082007;83(3):217\u2013224","DOI":"10.2223\/JPED.1600"},{"key":"2021120902382155300_R17","unstructured":"Vesikari T, Karvonen A, Prymula R, et al. Immunogenicity and reactogenicity of Rotarix, an oral human rotavirus vaccine, when co-administered with specific childhood vaccinations in healthy infants in Europe. Presented at: ESPID; European Society for Paediatric Infections; May 3\u20135, 2006; Basel, Switzerland"},{"key":"2021120902382155300_R18","doi-asserted-by":"crossref","unstructured":"O'Ryan M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev Vaccines.\u20082007;6(1):11\u201319","DOI":"10.1586\/14760584.6.1.11"},{"key":"2021120902382155300_R19","doi-asserted-by":"crossref","unstructured":"Matson DO, O'Ryan ML, Herrera I, Pickering LK, Estes MK. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis.\u20081993;167(3):577\u2013583","DOI":"10.1093\/infdis\/167.3.577"},{"key":"2021120902382155300_R20","doi-asserted-by":"crossref","unstructured":"Coulson BS, Grimwood K, Hudson IL, Barnes GL, Bishop RF. Role of coproantibody in clinical protection of children during reinfection with rotavirus. J Clin Microbiol.\u20081992;30(7):1678\u20131684","DOI":"10.1128\/jcm.30.7.1678-1684.1992"},{"key":"2021120902382155300_R21","doi-asserted-by":"crossref","unstructured":"Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine.\u20082006;24(15):2718\u20132731","DOI":"10.1016\/j.vaccine.2005.12.048"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/122\/5\/e1062\/1177036\/zpe011080e1062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/122\/5\/e1062\/1177036\/zpe011080e1062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:01:49Z","timestamp":1684616509000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/122\/5\/e1062\/71455\/Coadministration-of-RIX4414-Oral-Human-Rotavirus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,1]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2008,11,1]]},"published-print":{"date-parts":[[2008,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-1059","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,1]]}}}